Portfolio

Company Announcements

Vernalis Results of Annual General Meeting

Related Companies

RNS Number : 7260Q
Vernalis PLC
01 December 2016
 

1 December 2016

 

LSE: VER

 

Vernalis Results of Annual General Meeting

 

Resolutions

 

Vernalis plc (LSE: VER) announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed.

 

All resolutions were approved on a show of hands.  The number of proxy votes received for each resolution is set out below.

 

Resolution

For (including discretionary votes)*

Against*

Withheld

Ordinary Resolutions (requires 50% majority)

1.   That the audited accounts and related reports of the directors and auditors for the 12 month period ended 30 June 2016 be received

481,517,407

(>99.99 %)

1,302

(<0.01 %)

178

2.   That the remuneration report contained within the report and accounts for the 12 month period ended 30 June 2016 be approved

474,876,956

(>98.62 %)

6,639,291

(<1.38 %)

2,640

3.   That Dr Fellner be re-elected as a director

479,611,759

(>99.99 %)

26,936

(<0.01 %)

1,880,192

4.   That Ms Ferguson be re-elected as a director

479,635,151

(<99.61 %)

1,883,550

(>0.39 %)

186

5.   That Mr Mackney be re-elected as a director

481,514,918

(>99.99 %)

3,708

(<0.01 %)

261

6.   That PricewaterhouseCoopers LLP be reappointed auditors and the directors be authorised to determine their remuneration

474,881,144

(>98.62 %)

6,637,552

(<1.38 %)

191

7.   That the directors be authorised to allot shares

479,617,975

(>99.99 %)

19,306

(<0.01 %)

1,881,606

Special Resolutions (requires 75% majority)

8.   That the directors be authorised to disapply pre-emption rights

481,478,371

(>99.99 %)

36,956

(<0.01 %)

3,560

9.   That the directors be authorised to disapply pre-emption rights in connection with an acquisition or specified capital investment

479,598,409

(>99.60 %)

1,916,786

(<0.40 %)

3,692

*NB: A vote withheld is not a vote in law and, is not counted in the calculation of the votes for or against a resolution.  Therefore, the percentage of votes cast excludes withheld votes

 

On 1 December 2016, there were 526,352,521 Vernalis plc ordinary shares in issue.  Shareholders are entitled to one vote per share held.

 

The full text of each resolution passed at the Annual General Meeting held earlier today, Thursday 1 December 2016, is set out in the Notice of Annual General Meeting which is available for viewing on the Company's website at www.vernalis.com.

 

-- ends -

 

 

Enquiries:

 

Vernalis:

+44 (0) 118 938 0015

Ian Garland, Chief Executive Officer

David Mackney, Chief Financial Officer

 


Canaccord Genuity Limited (Nominated Adviser and Joint Broker):

+44 (0) 20 7523 8350

Dr Julian Feneley

Henry Fitzgerald-O'Connor

Rupert Winkler

Emma Gabriel

 


Shore Capital  (Joint Broker):

+44 (0)20 7408 4090

Bidhi Bhoma

Toby Gibbs

 


FTI Consulting:

+44 (0) 20 3727 1000

Ben Atwell

Simon Conway

Stephanie Cuthbert


 

Notes to Editors

 

About Vernalis

Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development.  The Group has three approved products: Tuzistra® XR targeting the US prescription cough-cold market; Moxatag®, a once-a-day formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine.  It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough-cold market as well as eight programmes in its NCE development pipeline.  Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies.  The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier, Taisho, and Tris.

                                                                

For further information about Vernalis, please visit www.vernalis.com.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGLLFEFFALLIIR

Top of Page